Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D.,
will join the company as Chief Strategy and Innovation Officer,
Executive Vice President. Dr. Baum will be a member of Pfizer’s
Executive Leadership Team reporting to Chairman and Chief Executive
Officer, Dr. Albert Bourla. He joins Pfizer from Citi, where he
served as Head of Global Healthcare, Managing Director Equity
Research. Prior to joining Citi in 2011, Dr. Baum covered European
Pharmaceuticals at Morgan Stanley for 14 years and earlier in his
career was a practicing physician at the Royal National Orthopaedic
Radcliffe Hospital in Oxford where he completed his residency.
At Pfizer, Dr. Baum will play a vital role in advancing Pfizer’s
long-term corporate strategic plan to maximize value for patients
and shareholders. He will also be responsible for our portfolio
analysis and prioritization functions, business development
activities, strengthening our partnerships with the biotech
ecosystem, and the commercial evaluation of our research pipeline.
In his role, he will also Chair Pfizer’s Portfolio Management Team,
the company’s most senior governing body responsible for portfolio
management and capital deployment across the company’s research and
development pipeline, ensuring that the company brings forward
vaccines and medicines that have the greatest potential of
addressing unmet patient needs while achieving robust reimbursement
and access. Dr. Baum will begin his role at Pfizer on June 3, 2024,
succeeding Aamir Malik, who recently moved into a new role at
Pfizer as Chief U.S. Commercial Officer, Executive Vice
President.
“Dr. Baum has a rare profile that combines deep clinical and
scientific knowledge with strong financial expertise in fields such
as equity research, hedge funds, investment banking and shareholder
value creation strategies. As a former experienced analyst who
followed Pfizer for over a decade, he will bring fresh strategic
insights into the company’s business and portfolio,” said Dr.
Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Dr.
Baum has more than 30 years of experience and a proven track record
in leading high-impact research projects and teams, developing
robust strategies and forging global partnerships that have
expanded markets and increased investor returns. I am delighted to
welcome Andrew to Pfizer where he will be an important thought
partner for me and my leadership team as we continue to advance
impactful vaccines and therapies that deliver value for patients,
health systems and shareholders.”
Dr. Baum holds a Master of Arts degree in Physiological Sciences
and a Bachelor of Medicine, Bachelor of Surgery (BM ChB) degree
from Oxford University and is a Fellow of the Royal Society of
Medicine. Dr. Baum also has a strong background in oncology and was
the first analyst to report on the transformative opportunity of
cancer immunotherapy in 2011. He is the former co-chair of
Immuno-Oncology 360° (IO360°).
"I am thrilled to be joining Pfizer as Chief Strategy and
Innovation Officer. I look forward to leveraging my prior
experience to help Pfizer identify, accelerate and deliver more
breakthrough therapies with the power to transform patients’
lives,” said Andrew Baum, M.D. “Pfizer is well placed to accelerate
its growth given its deep current expertise in small molecules,
antibody engineering and innovative vaccines.”
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
175 years, we have worked to make a difference for all who rely on
us. We routinely post information that may be important to
investors on our website at www.Pfizer.com. In addition, to learn
more, please visit us on www.Pfizer.com and follow us on X at
@Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook
at Facebook.com/Pfizer.
Disclosure Notice: The information contained in this
release is as of May 6, 2024. The Company assumes no obligation to
update forward-looking statements contained in this release as the
result of new information or future events or developments.
This release contains forward-looking statements about, among
other things, Pfizer’s growth potential, business plan, strategy,
prospects, pipeline and products and product candidates, including
their potential benefits, that involves substantial risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. Risks and
uncertainties include, among other things, the uncertainties
inherent in research and development, including the ability to meet
anticipated clinical endpoints, commencement and/or completion
dates for our clinical trials, regulatory submission dates,
regulatory approval dates and/or launch dates, as well as the
possibility of unfavorable new clinical data and further analyses
of existing clinical data; risks associated with interim and
preliminary data; the risk that clinical trial data are subject to
differing interpretations and assessments by regulatory
authorities; whether regulatory authorities will be satisfied with
the design of and results from our clinical studies; whether and
when any drug applications, biologics license applications and/or
emergency use authorization applications may be filed in any
jurisdictions for any potential indication for Pfizer’s product
candidates; whether and when any such applications that may be
pending or filed for any of Pfizer’s product candidates may be
approved by regulatory authorities, which will depend on myriad
factors, including making a determination as to whether the
product's benefits outweigh its known risks and determination of
the product's efficacy and, if approved, whether any such product
candidates will be commercially successful; decisions by regulatory
authorities impacting labeling, manufacturing processes, safety
and/or other matters that could affect the availability or
commercial potential of Pfizer’s product candidates, including
development of products or therapies by other companies;
manufacturing capabilities or capacity; uncertainties regarding the
ability to obtain recommendations from vaccine technical committees
and other public health authorities and uncertainties regarding the
commercial impact of any such recommendations; risks related to the
ability to realize the anticipated benefits of Pfizer’s business
development transactions, including the possibility that the
expected benefits from such transactions will not be realized or
will not be realized within the expected time period; uncertainties
regarding the commercial potential of Pfizer’s products and product
candidates; the uncertainties inherent in business and financial
planning, including, without limitation, risks related to Pfizer’s
business and prospects, adverse developments in Pfizer’s markets,
or adverse developments in the U.S. or global capital markets,
credit markets, regulatory environment or economies generally; the
impact of COVID-19 on our business, operations and financial
results; and competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2023 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
Category: Corporate, Leadership
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506861564/en/
Media Contact: PfizerMediaRelations@Pfizer.com +1 (212)
733-1226
Investor Contact: IR@Pfizer.com +1 (212) 733-4848
Pfizer (NYSE:PFE)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Pfizer (NYSE:PFE)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024